Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 172458, 13 pages
http://dx.doi.org/10.1155/2015/172458
Review Article

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling

1Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, 43126 Parma, Italy
2UO di Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, Italy

Received 11 August 2015; Revised 22 September 2015; Accepted 27 September 2015

Academic Editor: Mariateresa Fulciniti

Copyright © 2015 Fabrizio Accardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. D. Roodman, “Pathogenesis of myeloma bone disease,” Blood Cells, Molecules, and Diseases, vol. 32, no. 2, pp. 290–292, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Giuliani, V. Rizzoli, and G. D. Roodman, “Multiple myeloma bone disease: pathophysiology of osteoblast inhibition,” Blood, vol. 108, no. 13, pp. 3992–3996, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. R. A. Kyle, M. A. Gertz, T. E. Witzig et al., “Review of 1027 patients with newly diagnosed multiple myeloma,” in Mayo Clinic Proceedings, pp. 21–33, Elsevier, 2003. View at Google Scholar
  4. M. Sonmez, T. Akagun, M. Topbas et al., “Effect of pathologic fractures on survival in multiple myeloma patients: a case control study,” Journal of Experimental and Clinical Cancer Research, vol. 27, article 11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Terpos, L. A. Moulopoulos, and M. A. Dimopoulos, “Advances in imaging and the management of myeloma bone disease,” Journal of Clinical Oncology, vol. 29, no. 14, pp. 1907–1915, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. Pianko, E. Terpos, G. D. Roodman et al., “Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease,” Clinical Cancer Research, vol. 20, no. 23, pp. 5888–5897, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. A. Dimopoulos, J. Hillengass, S. Usmani et al., “Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement,” Journal of Clinical Oncology, vol. 33, no. 6, pp. 657–664, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. T. B. Bartel, J. Haessler, T. L. Y. Brown et al., “F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma,” Blood, vol. 114, no. 10, pp. 2068–2076, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Zamagni, F. Patriarca, C. Nanni et al., “Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation,” Blood, vol. 118, no. 23, pp. 5989–5995, 2011. View at Publisher · View at Google Scholar
  10. G. D. Roodman, “Mechanisms of bone metastasis,” The New England Journal of Medicine, vol. 350, no. 16, pp. 1655–1664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Raje and G. D. Roodman, “Advances in the biology and treatment of bone disease in multiple myeloma,” Clinical Cancer Research, vol. 17, no. 6, pp. 1278–1286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Giuliani and V. Rizzoli, “Myeloma cells and bone marrow osteoblast interactions: role in the development of osteolytic lesions in multiple myeloma,” Leukemia and Lymphoma, vol. 48, no. 12, pp. 2323–2329, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Terpos, R. Szydlo, J. F. Apperley et al., “Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index,” Blood, vol. 102, no. 3, pp. 1064–1069, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Roux, V. Meignin, J. Quillard et al., “RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma,” British Journal of Haematology, vol. 117, no. 1, pp. 86–92, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. R. N. Pearse, E. M. Sordillo, S. Yaccoby et al., “Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 20, pp. 11581–11586, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Yaccoby, R. N. Pearse, C. L. Johnson, B. Barlogie, Y. Choi, and J. Epstein, “Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity,” British Journal of Haematology, vol. 116, no. 2, pp. 278–290, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. A. N. Nguyen, E. G. Stebbins, M. Henson et al., “Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation,” Experimental Cell Research, vol. 312, no. 10, pp. 1909–1923, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Vanderkerken, S. Medicherla, L. Coulton et al., “Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma,” Cancer Research, vol. 67, no. 10, pp. 4572–4577, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-H. Man, S. J. Choi, N. Kurihara, M. Koide, Y. Oba, and G. David Roodman, “Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand,” Blood, vol. 97, no. 11, pp. 3349–3353, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Magrangeas, V. Nasser, H. Avet-Loiseau et al., “Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease,” Blood, vol. 101, no. 12, pp. 4998–5006, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. S. J. Choi, Y. Oba, Y. Gazitt et al., “Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease,” The Journal of Clinical Investigation, vol. 108, no. 12, pp. 1833–1841, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. J. W. Lee, H. Y. Chung, L. A. Ehrlich et al., “IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells,” Blood, vol. 103, no. 6, pp. 2308–2315, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Vallet, S. Mukherjee, N. Vaghela et al., “Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 11, pp. 5124–5129, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Silbermann, M. Bolzoni, P. Storti et al., “Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma,” Leukemia, vol. 28, no. 4, pp. 951–954, 2013. View at Publisher · View at Google Scholar
  25. T. Vejlgaard, N. Abildgaard, H. Jans, J. L. Nielsen, and L. Heickendorff, “Abnormal bone turnover in monoclonal gammopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens,” European Journal of Haematology, vol. 58, no. 2, pp. 104–108, 1997. View at Google Scholar · View at Scopus
  26. T. Kobayashi and H. Kronenberg, “Minireview: transcriptional regulation in development of bone,” Endocrinology, vol. 146, no. 3, pp. 1012–1017, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Giuliani, S. Colla, F. Morandi et al., “Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation,” Blood, vol. 106, no. 7, pp. 2472–2483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. S. D'Souza, D. del Prete, S. Jin et al., “Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease,” Blood, vol. 118, no. 26, pp. 6871–6880, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Jin, H. Zeng, K.-W. Schmid, M. Toetsch, S. Uhlig, and T. Möröy, “The zinc finger protein Gfi1 acts upstream of TNF to attenuate endotoxin-mediated inflammatory responses in the lung,” European Journal of Immunology, vol. 36, no. 2, pp. 421–430, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Giuliani, S. Colla, R. Sala et al., “Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease,” Blood, vol. 100, no. 13, pp. 4615–4621, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Mukai, F. Otsuka, H. Otani et al., “TNF-alpha inhibits BMP-induced osteoblast differentiation through activating SAPK/JNK signaling,” Biochemical and Biophysical Research Communications, vol. 356, no. 4, pp. 1004–1010, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Gilbert, X. He, P. Farmer et al., “Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha,” The Journal of Biological Chemistry, vol. 277, no. 4, pp. 2695–2701, 2002. View at Publisher · View at Google Scholar
  33. L. A. Ehrlich, H. Y. Chung, I. Ghobrial et al., “EL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma,” Blood, vol. 106, no. 4, pp. 1407–1414, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. C. M. Edwards, J. R. Edwards, S. T. Lwin et al., “Increasing wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo,” Blood, vol. 111, no. 5, pp. 2833–2842, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. C. M. Edwards, J. Zhuang, and G. R. Mundy, “The pathogenesis of the bone disease of multiple myeloma,” Bone, vol. 42, no. 6, pp. 1007–1013, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. N. Giuliani, F. Morandi, S. Tagliaferri et al., “Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment,” Cancer Research, vol. 67, no. 16, pp. 7665–7674, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Tian, F. Zhan, R. Walker et al., “The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma,” The New England Journal of Medicine, vol. 349, no. 26, pp. 2483–2494, 2003. View at Publisher · View at Google Scholar
  38. J. Li, I. Sarosi, R. C. Cattley et al., “Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia,” Bone, vol. 39, no. 4, pp. 754–766, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. J. J. Westendorf, R. A. Kahler, and T. M. Schroeder, “Wnt signaling in osteoblasts and bone diseases,” Gene, vol. 341, no. 1-2, pp. 19–39, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. C. E. Evans, C. Ward, L. Rathour, and C. B. Galasko, “Myeloma affects both the growth and function of human osteoblast-like cells,” Clinical and Experimental Metastasis, vol. 10, no. 1, pp. 33–38, 1992. View at Publisher · View at Google Scholar · View at Scopus
  41. F. Silvestris, P. Cafforio, M. Tucci, D. Grinello, and F. Dammacco, “Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease,” British Journal of Haematology, vol. 122, no. 1, pp. 39–52, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Tinhofer, R. Biedermann, M. Krismer, R. Crazzolara, and R. Greil, “A role of TRAIL in killing osteoblasts by myeloma cells,” The FASEB Journal, vol. 20, no. 6, pp. 759–761, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. L. F. Bonewald, “The amazing osteocyte,” Journal of Bone and Mineral Research, vol. 26, no. 2, pp. 229–238, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. B. S. Noble and J. Reeve, “Osteocyte function, osteocyte death and bone fracture resistance,” Molecular and Cellular Endocrinology, vol. 159, no. 1-2, pp. 7–13, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. N. Giuliani, M. Ferretti, M. Bolzoni et al., “Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation,” Leukemia, vol. 26, no. 6, pp. 1391–1401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Gu, M. Mulari, Z. Peng, T. A. Hentunen, and H. K. Väänänen, “Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption,” Biochemical and Biophysical Research Communications, vol. 335, no. 4, pp. 1095–1101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. I. M. Konstantinova, A. S. Tsimokha, and A. G. Mittenberg, “Role of proteasomes in cellular regulation,” International Review of Cell and Molecular Biology, vol. 267, pp. 59–124, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. P. J. Eiott and J. Adams, “Recent advances in understanding proteasome function,” Current Opinion in Drug Discovery and Development, vol. 2, no. 5, pp. 484–490, 1999. View at Google Scholar · View at Scopus
  49. L. J. Crawford and A. E. Irvine, “Targeting the ubiquitin proteasome system in haematological malignancies,” Blood Reviews, vol. 27, no. 6, pp. 297–304, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. K. R. Landis-Piwowar, V. Milacic, D. Chen et al., “The proteasome as a potential target for novel anticancer drugs and chemosensitizers,” Drug Resistance Updates, vol. 9, no. 6, pp. 263–273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Groll, L. Ditzel, J. Löwe et al., “Structure of 20S proteasome from yeast at 2.4 Å resolution,” Nature, vol. 386, no. 6624, pp. 463–471, 1997. View at Publisher · View at Google Scholar · View at Scopus
  52. J. P. McGrath, S. Jentsch, and A. Varshavsky, “UBA 1: an essential yeast gene encoding ubiquitin-activating enzyme,” The EMBO Journal, vol. 10, no. 1, pp. 227–236, 1991. View at Google Scholar · View at Scopus
  53. W. Heinemeyer, M. Fischer, T. Krimmer, U. Stachon, and D. H. Wolf, “The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing,” The Journal of Biological Chemistry, vol. 272, no. 40, pp. 25200–25209, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. E. A. Obeng, L. M. Carlson, D. M. Gutman, W. J. Harrington Jr., K. P. Lee, and L. H. Boise, “Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells,” Blood, vol. 107, no. 12, pp. 4907–4916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Cenci, A. Mezghrani, P. Cascio et al., “Progressively impaired proteasomal capacity during terminal plasma cell differentiation,” The EMBO Journal, vol. 25, no. 5, pp. 1104–1113, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Cenci, L. Oliva, F. Cerruti et al., “Pivotal advance: protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors,” Journal of Leukocyte Biology, vol. 92, no. 5, pp. 921–931, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Zinszner, M. Kuroda, X. Wang et al., “CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum,” Genes & Development, vol. 12, no. 7, pp. 982–995, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. J. W. Brewer and J. A. Diehl, “PERK mediates cell-cycle exit during the mammalian unfolded protein response,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 23, pp. 12625–12630, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Meister, U. Schubert, K. Neubert et al., “Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition,” Cancer Research, vol. 67, no. 4, pp. 1783–1792, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. K. D. McCullough, J. L. Martindale, L.-O. Klotz, T.-Y. Aw, and N. J. Holbrook, “Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating Bcl2 and perturbing the cellular redox state,” Molecular and Cellular Biology, vol. 21, no. 4, pp. 1249–1259, 2001. View at Publisher · View at Google Scholar · View at Scopus
  61. C. S. Mitsiades, N. Mitsiades, V. Poulaki et al., “Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications,” Oncogene, vol. 21, no. 37, pp. 5673–5683, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Chauhan, H. Uchiyama, Y. Akbarali et al., “Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB,” Blood, vol. 87, no. 3, pp. 1104–1112, 1996. View at Google Scholar · View at Scopus
  63. T. Hideshima, D. Chauhan, P. Richardson et al., “NF-kappa B as a therapeutic target in multiple myeloma,” The Journal of Biological Chemistry, vol. 277, no. 19, pp. 16639–16647, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. V. J. Palombella, O. J. Rando, A. L. Goldberg, and T. Maniatis, “The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB,” Cell, vol. 78, no. 5, pp. 773–785, 1994. View at Publisher · View at Google Scholar · View at Scopus
  65. I. Zavrski, H. Krebbel, B. Wildemann et al., “Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function,” Biochemical and Biophysical Research Communications, vol. 333, no. 1, pp. 200–205, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. I. von Metzler, H. Krebbel, M. Hecht et al., “Bortezomib inhibits human osteoclastogenesis,” Leukemia, vol. 21, no. 9, pp. 2025–2034, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Pennisi, X. Li, W. Ling, S. Khan, M. Zangari, and S. Yaccoby, “The proteasome Inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo,” American Journal of Hematology, vol. 84, no. 1, pp. 6–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. M. A. Hurchla, A. Garcia-Gomez, M. C. Hornick et al., “The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects,” Leukemia, vol. 27, no. 2, pp. 430–440, 2013. View at Publisher · View at Google Scholar · View at Scopus
  69. I. R. Garrett, D. Chen, G. Gutierrez et al., “Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro,” The Journal of Clinical Investigation, vol. 111, no. 11, pp. 1771–1782, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. R. C. Kane, P. F. Bross, A. T. Farrell, and R. Pazdur, “Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy,” Oncologist, vol. 8, no. 6, pp. 508–513, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. R. C. Kane, A. T. Farrell, R. Sridhara, and R. Pazdur, “United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy,” Clinical Cancer Research, vol. 12, no. 10, pp. 2955–2960, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. P. G. Richardson, C. Mitsiades, R. Schlossman et al., “Bortezomib in the front-line treatment of multiple myeloma,” Expert Review of Anticancer Therapy, vol. 8, no. 7, pp. 1053–1072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. C. R. Berkers, M. Verdoes, E. Lichtman et al., “Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib,” Nature Methods, vol. 2, no. 5, pp. 357–362, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Groll, C. R. Berkers, H. L. Ploegh, and H. Ovaa, “Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome,” Structure, vol. 14, no. 3, pp. 451–456, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. C. M. Edwards, S. T. Lwin, J. A. Fowler et al., “Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo,” American Journal of Hematology, vol. 84, no. 5, pp. 268–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. N. Giuliani, F. Morandi, S. Tagliaferri et al., “The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients,” Blood, vol. 110, no. 1, pp. 334–338, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. Y.-W. Qiang, B. Hu, Y. Chen et al., “Bortezomib induces osteoblast differentiation via Wnt-independent activation of β-catenin/TCF signaling,” Blood, vol. 113, no. 18, pp. 4319–4330, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. S. Mukherjee, N. Raje, J. A. Schoonmaker et al., “Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice,” The Journal of Clinical Investigation, vol. 118, no. 2, pp. 491–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. B. O. Oyajobi, I. R. Garrett, A. Gupta et al., “Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease,” British Journal of Haematology, vol. 139, no. 3, pp. 434–438, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Uyama, M. M. Sato, M. Kawanami, and M. Tamura, “Regulation of osteoblastic differentiation by the proteasome inhibitor bortezomib,” Genes to Cells, vol. 17, no. 7, pp. 548–558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Piek, L. S. Sleumer, E. P. van Someren et al., “Osteo-transcriptomics of human mesenchymal stem cells: accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis,” Bone, vol. 46, no. 3, pp. 613–627, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. R. St-Arnaud, “The direct role of vitamin D on bone homeostasis,” Archives of Biochemistry and Biophysics, vol. 473, no. 2, pp. 225–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. F. Kaiser, U. Heider, M. Mieth, C. Zang, I. von Metzler, and O. Sezer, “The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling,” European Journal of Haematology, vol. 90, no. 4, pp. 263–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. D. Toscani, C. Palumbo, B. Dalla Palma et al., “Myeloma-induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy,” Blood, vol. 122, no. 21, p. 3096, 2013. View at Google Scholar
  85. S. Lonial, C. S. Mitsiades, and P. G. Richardson, “Treatment options for relapsed and refractory multiple myeloma,” Clinical Cancer Research, vol. 17, no. 6, pp. 1264–1277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Meng, R. Mohan, B. H. B. Kwok, M. Elofsson, N. Sin, and C. M. Crews, “Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 18, pp. 10403–10408, 1999. View at Publisher · View at Google Scholar · View at Scopus
  87. S. D. Demo, C. J. Kirk, M. A. Aujay et al., “Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome,” Cancer Research, vol. 67, no. 13, pp. 6383–6391, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. O. A. O'Connor, A. K. Stewart, M. Vallone et al., “A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies,” Clinical Cancer Research, vol. 15, no. 22, pp. 7085–7091, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. D. J. Kuhn, Q. Chen, P. M. Voorhees et al., “Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma,” Blood, vol. 110, no. 9, pp. 3281–3290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Hu, Y. Chen, S. Z. Usmani et al., “Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma,” PLoS ONE, vol. 8, no. 9, Article ID e74191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Li, J. Li, W. Zhuang et al., “Carfilzomib promotes the osteogenic differentiation potential of mesenchymal stem cells derived from myeloma patients by inhibiting notch1 activity in vitro,” Leukemia Research, vol. 38, no. 8, pp. 970–976, 2014. View at Publisher · View at Google Scholar · View at Scopus
  92. M. J. Hilton, X. Tu, X. Wu et al., “Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation,” Nature Medicine, vol. 14, no. 3, pp. 306–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  93. N. Xu, H. Liu, F. Qu et al., “Hypoxia inhibits the differentiation of mesenchymal stem cells into osteoblasts by activation of Notch signaling,” Experimental and Molecular Pathology, vol. 94, no. 1, pp. 33–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. Y. Yang, H. C. Blair, I. M. Shapiro, and B. Wang, “The proteasome inhibitor carfilzomib suppresses parathyroid hormone-induced osteoclastogenesis through a RANKL-mediated signaling pathway,” Journal of Biological Chemistry, vol. 290, no. 27, pp. 16918–16928, 2015. View at Publisher · View at Google Scholar
  95. V. R. Macherla, S. S. Mitchell, R. R. Manam et al., “Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor,” Journal of Medicinal Chemistry, vol. 48, no. 11, pp. 3684–3687, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. B. C. Potts, M. X. Albitar, K. C. Anderson et al., “Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials,” Current Cancer Drug Targets, vol. 11, no. 3, pp. 254–284, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. C. P. Miller, C. A. Manton, R. Hale et al., “Specific and prolonged proteasome inhibition dictates apoptosis induction by marizomib and its analogs,” Chemico-Biological Interactions, vol. 194, no. 1, pp. 58–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Chauhan, L. Catley, G. Li et al., “A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib,” Cancer Cell, vol. 8, no. 5, pp. 407–419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. K. S. Ahn, G. Sethi, T.-H. Chao et al., “Salinosporamide a (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-κB-regulated gene products,” Blood, vol. 110, no. 7, pp. 2286–2295, 2007. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Garcia-Gomez, D. Quwaider, M. Canavese et al., “Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease,” Clinical Cancer Research, vol. 20, no. 6, pp. 1542–1554, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. E. C. Lee, M. Fitzgerald, B. Bannerman et al., “Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies,” Clinical Cancer Research, vol. 17, no. 23, pp. 7313–7323, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. E. M. Ocio, M.-V. Mateos, and J. F. San-Miguel, “Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs,” Expert Opinion on Investigational Drugs, vol. 21, no. 8, pp. 1075–1087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Kupperman, E. C. Lee, Y. Cao et al., “Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer,” Cancer Research, vol. 70, no. 5, pp. 1970–1980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Chauhan, A. V. Singh, M. Aujay et al., “A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma,” Blood, vol. 116, no. 23, pp. 4906–4915, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Piva, B. Ruggeri, M. Williams et al., “CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib,” Blood, vol. 111, no. 5, pp. 2765–2775, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. C. R. Berkers, Y. Leestemaker, K. G. Schuurman et al., “Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib,” Molecular Pharmaceutics, vol. 9, no. 5, pp. 1126–1135, 2012. View at Publisher · View at Google Scholar · View at Scopus
  107. E. Sanchez, M. Li, J. Li et al., “CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma,” Leukemia Research, vol. 36, no. 11, pp. 1422–1427, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. E. Sanchez, M. Li, J. A. Steinberg et al., “The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan,” British Journal of Haematology, vol. 148, no. 4, pp. 569–581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Zangari, D. Esseltine, C.-K. Lee et al., “Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma,” British Journal of Haematology, vol. 131, no. 1, pp. 71–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  110. P. G. Richardson, B. Barlogie, J. Berenson et al., “A phase 2 study of Bortezomib in relapsed, refractory myeloma,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2609–2617, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. P. G. Richardson, P. Sonneveld, M. W. Schuster et al., “Bortezomib or high-dose dexamethasone for relapsed multiple myeloma,” The New England Journal of Medicine, vol. 352, no. 24, pp. 2487–2498, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. M. Zangari, S. Yaccoby, F. Cavallo, D. Esseltine, and G. Tricot, “Response to bortezomib and activation of osteoblasts in multiple myeloma,” Clinical Lymphoma and Myeloma, vol. 7, no. 2, pp. 109–114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Zangari, M. Aujay, F. Zhan et al., “Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients,” European Journal of Haematology, vol. 86, no. 6, pp. 484–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  114. C. Shimazaki, R. Uchida, S. Nakano et al., “High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation,” Leukemia, vol. 19, no. 6, pp. 1102–1103, 2005. View at Publisher · View at Google Scholar · View at Scopus
  115. U. Heider, M. Kaiser, C. Müller et al., “Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment,” European Journal of Haematology, vol. 77, no. 3, pp. 233–238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Ozaki, O. Tanaka, S. Fujii et al., “Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma,” International Journal of Hematology, vol. 86, no. 2, pp. 180–185, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. T. Lund, K. Søe, N. Abildgaard et al., “First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro,” European Journal of Haematology, vol. 85, no. 4, pp. 290–299, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. Delforge, E. Terpos, P. G. Richardson et al., “Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma,” European Journal of Haematology, vol. 86, no. 5, pp. 372–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. E. Terpos, D. J. Heath, A. Rahemtulla et al., “Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma,” British Journal of Haematology, vol. 135, no. 5, pp. 688–692, 2006. View at Publisher · View at Google Scholar · View at Scopus
  120. K.-S. Eom, S. J. Kim, J.-J. Lee et al., “Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study,” BioMed Research International, vol. 2014, Article ID 245247, 7 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Terpos, D. Christoulas, E. Kastritis et al., “The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group,” American Journal of Hematology, vol. 89, no. 1, pp. 34–40, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. E. Terpos, M. A. Dimopoulos, O. Sezer et al., “The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group,” Leukemia, vol. 24, no. 10, pp. 1700–1712, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. P. Boissy, T. L. Andersen, T. Lund, K. Kupisiewicz, T. Plesner, and J. M. Delaissé, “Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions,” Leukemia Research, vol. 32, no. 11, pp. 1661–1668, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. E. Terpos, D. Christoulas, P. Kokkoris et al., “Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid,” Annals of Oncology, vol. 21, no. 7, pp. 1561–1562, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Zangari, T. Berno, M. E. Salama et al., “Effect of low dose bortezomib on bone formation in smoldering myeloma patients,” Blood, vol. 122, no. 21, pp. 3204–3204, 2013. View at Google Scholar
  126. S.-E. Lee, C.-K. Min, S.-A. Yahng et al., “Bone scan images reveal increased osteoblastic function after bortezomib treatment in patients with multiple myeloma,” European Journal of Haematology, vol. 86, no. 1, pp. 83–86, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Zangari, S. Yaccoby, L. Pappas et al., “A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients,” Haematologica, vol. 96, no. 2, pp. 333–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. M. Schulze, K. Weisel, C. Grandjean et al., “Increasing bone sclerosis during bortezomib therapy in multiple myeloma patients: results of a reduced-dose whole-body MDCT study,” American Journal of Roentgenology, vol. 202, no. 1, pp. 170–179, 2014. View at Publisher · View at Google Scholar · View at Scopus